Finoriq research workspace

Krystal Biotech, Inc. (KRYS) Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures. Review KRYS filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Company

Krystal Biotech, Inc. (KRYS)

Ticker

KRYS

Market Cap

$10.1B

Latest Price

$341.71

Industry

Biotech & Pharma

Open insider transactions

Krystal Biotech, Inc. (KRYS) Current Valuation Metrics

Static valuation preview for Krystal Biotech, Inc. (KRYS). Market data retrieved 2026-07-08. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.